Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that management will be hosting investor meetings at the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel in Boston, Massachusetts.

Investors attending the conference who are interested in meeting with Ocular Therapeutix management should contact their Guggenheim Securities representative.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

InvestorsOcular TherapeutixDonald NotmanChief Financial Officerdnotman@ocutx.comorWestwicke PartnersChris Brinzey, 339-970-2843chris.brinzey@westwicke.comorMediaOcular TherapeutixScott CorningVice President of Marketing & Commercial Operationsscorning@ocutx.com

Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Ocular Therapeutix Charts.
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Ocular Therapeutix Charts.